Live Interview to Air February 21, 2015, Hosted by Ben Chodor, 3:00pm ET/12:00pm PT/2:00pm CT
CORAL SPRINGS, FL--(Marketwired - Feb 20, 2015) - Nutra Pharma Corporation (OTC PINK: NPHC), a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases, announced today that Chairman and Chief Executive Officer (CEO) Rik J. Deitsch will be interviewed live on iHeart Radio's Health Tech Talk Live hosted by Ben Chodor and broadcasted nationwide on iHeart Radio / Clear Channel Atlanta Studios - 640 WGST AM this Saturday at 3:00pm ET. In this exclusive double-segment interview, Mr. Deitsch will discuss how Nutra Pharma is currently expanding its OTC retail sales of their pain therapies: Nyloxin® and Pet Pain-Away. He also discusses the clinical development of its first two therapeutic products. Shareholders, analysts, industry professionals and all interested parties are encouraged to listen live via Clear Channel's nationally syndicated iHeart Radio stream.
Date: February 21, 2015
Start Time: 3:00pm ET | 12:00pm PT | 2:00pm CT (U.S.)
Network: iHeart Radio / Clear Channel
Station: 640 WGST AM
Show: HealthTech Talk Live
Host: Ben Chodor
About Nutra Pharma Corporation
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. The Company currently markets drug products for the treatment of pain under the brands Nyloxin® and Pet Pain-Away.
About CEO Rik J. Deitsch
Nutra Pharma's Chairman and Chief Executive Officer holds both a B.S. in Chemistry and an M.S. in Biochemistry and has conducted clinical and laboratory research in collaboration with scientists at Duke University Medical Center and the Cleveland Clinic. Mr. Deitsch is the author of two books: Are You AgeWise: A Guide to Healthy Aging, and Invisible Killers: the Truth About Environmental Genocide. He is also an adjunct professor, teaching several courses for Florida Atlantic University's College of Business and Continuing Education Department.
About iHeart Radio/ Clear Channel
Clear Channel's Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. For more Information Visit: http://www.iheart.com/live/talk-radio-640-wgst-6066/?autoplay=true&pname=15153&campid=play_bar&cid=main.html.
About HealthTech Talk Live
HealthTech Talk Live broadcasts live weekly on iHeart Radio / Clear Channel nationwide from 640 WGST AM Atlanta, 3:00pm - 4:00pm EST every Saturday. Host Ben Chodor interviews the front-page emerging health tech innovators and titans about the latest in digital health technology, human ingenuity, bio-tech medical advancements and health tech capital market trends. Learn how the experts use risk management techniques and clinical trials to build fully diversified portfolios and what it takes to put up big board earnings from making people healthier. It's a fast moving, high-energy show... shift your thinking and join us as we deliver "tomorrow's ideas today" on iHeart Radio and Clear Channel's HealthTech Talk Live. Visit iHeart Radio's HealthTech Talk Radio Show or visit www.HealthTechTalk.com. If you're interested in being a guest on HealthTech Talk Live radio show, please contact 1800PublicRelations at email@example.com "ATTN: Health Tech Talk Guest Inquiry."
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2769948
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2769950
Nutra Pharma Corp.
Interview Press/ Media
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The interview with the Company's CEO should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.